Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Aclidinium Bromide

    Client Email Product

    Aclidinium Bromide

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    13
    US DMFs Filed

    US DMFs Filed

    4
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    1
    Other Certificates

    Other Certificates

    1
    Other Suppliers

    Other Suppliers

    11
    API REF. PRICE (USD / KG)

    0

    API Market Place

    2
    INTERMEDIATES
    4
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    2
    Europe

    Europe

    10
    Canada

    Canada

    2
    Australia

    Australia

    2
    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    326.00

    Annual Reports

    205.00

    FDF Market Place

    0

    EXCIPIENTS
    25
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    8

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    1

    News

    10
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    left grey arrow
    right gray arrow
    • POWDER, METERED;INHALATION - 0.4MG/INH
    • POWDER, METERED;INHALATION - 0.4MG/INH;0.012MG/INH
    Full View ScreenFull Screen View
    AZN completes transfer of global rights to Eklira & Duaklir to Covis Pharma
    AZN completes transfer of global rights to Eklira & Duaklir to Covis Pharma

    http://www.pharmabiz.com/NewsDetails.aspx?aid=145059&sid=2

    PHARMABIZ
    06 Jan 2022
    Share Share
    AstraZeneca sells 2 COPD inhalers to familiar face
    AstraZeneca sells 2 COPD inhalers to familiar face

    https://www.fiercepharma.com/pharma/astrazeneca-resumes-asset-sale-270m-copd-deal-familiar-buyer-covis

    Angus Liu FIERCEPHARMA
    02 Nov 2021
    Share Share
    A three-decade monopoly: How Amgen built a patent thicket top-selling drug
    A three-decade monopoly: How Amgen built a patent thicket top-selling drug

    https://www.biopharmadive.com/news/amgen-enbrel-patent-thicket-monopoly-biosimilar/609042/

    Jonathan Gardner BIOPHARMADIVE
    30 Oct 2021
    Share Share
    Circassia Pharmaceuticals launches DUAKLIR® PRESSAIR® for patients with COPD
    Circassia Pharmaceuticals launches DUAKLIR® PRESSAIR® for patients with COPD

    https://www.biospace.com/article/releases/circassia-pharmaceuticals-launches-duaklir-pressair-aclidinium-formoterol-for-patients-with-chronic-obstructive-pulmonary-disease-copd-/?s=95

    BIOSPACE
    21 Oct 2019
    Share Share
    US Food and Drug Administration Approves DUAKLIR® PRESSAIR®
    US Food and Drug Administration Approves DUAKLIR® PRESSAIR®

    https://www.businesswire.com/news/home/20190417005363/en/Food-Drug-Administration-Approves-DUAKLIR%C2%AE-PRESSAIR%C2%AE-aclidiniumformoterol/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==

    BUSINESSWIRE
    17 Apr 2019
    Share Share
    FDA Approves TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) sNDA)
    FDA Approves TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) sNDA)

    https://www.businesswire.com/news/home/20190329005556/en/FDA-Approves-TUDORZA%C2%AE-PRESSAIR%C2%AE-aclidinium-bromide-inhalation/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==

    BUSINESSWIRE
    01 Apr 2019
    Share Share
    AZ’ Tudorza hits study goals in COPD patients with CV risk factors
    AZ’ Tudorza hits study goals in COPD patients with CV risk factors

    http://www.pharmatimes.com/news/az_tudorza_hits_study_goals_in_copd_patients_with_cv_risk_factors_1213240

    Selina McKee PHARMA TIMES
    05 Dec 2017
    Share Share
    AZ announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD
    AZ announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD

    http://www.pharmabiz.com/NewsDetails.aspx?aid=105896&sid=2

    PHARMABIZ
    04 Dec 2017
    Share Share
    Five pharmas Fall Foul of ABPI Code of Practice
    Five pharmas Fall Foul of ABPI Code of Practice

    http://www.pharmatimes.com/news/five_pharmas_fall_foul_of_abpi_code_of_practice_1181699

    Selina McKee PHARMATIMES
    15 Dec 2016
    Share Share
    US FDA Enforcement report- 30/Mar/2016
    US FDA Enforcement report- 30/Mar/2016

    https://www.pharmacompass.com/pdf/news/us-fda-enforcement-report-30mar2016-1459335769.pdf

    FDA
    28 Mar 2016
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    inke Aclidinium Bromide

    Access Virtual Booth

    Contact Supplier

    View Presentation

    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search